Education
About Us
Working with TipRanks
Follow Us
Talis Biomedical (TLIS)
OTHER OTC:TLIS
Top Page
Talis Biomedical
(OTC:TLIS)
29Underperform
Talis Biomedical (TLIS) vs. S&P 500 (SPY)
Market Cap
$55.13M
Dividend YieldN/A
Average Volume (3M)1.52K
Price to Earnings (P/E)―
Beta (1Y)2.16
Revenue Growth-70.65%
EPS Growth41.59%
CountryUS
Employees99
SectorHealthcare
Sector Strength71
IndustryMedical - Devices
Share Statistics
EPS (TTM)-28.02
Shares Outstanding1,822,820
10 Day Avg. Volume440
30 Day Avg. Volume1,525
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.74
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Talis Biomedical Business Overview & Revenue Model
Company DescriptionTalis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
How the Company Makes MoneyTalis Biomedical generates revenue primarily through the sale of its diagnostic testing products. The company's core revenue stream comes from its point-of-care testing solutions that are sold to clinics, hospitals, and other healthcare facilities. These products are designed to offer quick and reliable test results, thus addressing the need for timely diagnostics in patient care. Additionally, Talis may engage in partnerships and collaborations with other healthcare organizations and research institutions, which can also contribute to its earnings through joint development agreements, licensing deals, or co-marketing strategies. The focus on delivering innovative and efficient diagnostic tools helps Talis Biomedical maintain its competitive edge and attract a steady customer base.
Talis Biomedical Financial Statement Overview
Summary
Talis Biomedical is facing significant financial challenges, with consistent net losses and negative cash flow. Despite improvements in gross profit margin and a sound equity base, the company struggles with declining revenues and high operational costs. These factors pose substantial risks to its financial health.Income Statement
Talis Biomedical has experienced a declining revenue trend, with a significant drop from $10.94 million in 2020 to $412,000 in 2023. The gross profit margin improved to 90% in 2023, indicating cost efficiencies, but the company remains unprofitable with a net loss margin of -15055%. EBIT and EBITDA margins are highly negative, pointing to ongoing operational challenges.20
Very Negative
Balance Sheet
The balance sheet reflects a high equity ratio of 73% in 2023, showing a solid equity base relative to assets. However, the debt-to-equity ratio increased slightly to 0.28, indicating a manageable but present level of leverage. The company has ample cash reserves, but the consistent losses could deplete resources over time.25
Negative
Cash Flow
Operating cash flow has been negative, reflecting cash outflows exceeding inflows, with a free cash flow of -$53.73 million in 2023. The free cash flow to net income ratio is unfavorable, indicating inefficiencies in converting net income into cash. The company has yet to generate positive cash flow from operations or investments.15
Very Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 300.00K | 412.00K | 3.65M | 0.00 | 10.94M | 3.98M | Gross Profit |
| -680.00K | 371.00K | -4.74M | -2.62M | 10.94M | 3.98M | EBIT |
| -50.20M | -66.81M | -115.14M | -191.82M | -91.18M | -26.70M | EBITDA |
| -54.01M | -66.05M | -106.31M | -191.82M | -90.42M | -25.97M | Net Income Common Stockholders |
| -51.03M | -62.01M | -110.89M | -190.46M | -91.08M | -27.43M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 70.34M | 76.73M | 130.19M | 232.54M | 138.48M | 21.60M | Total Assets |
| 82.49M | 94.67M | 169.29M | 265.83M | 198.41M | 25.73M | Total Debt |
| 19.24M | 19.67M | 33.58M | 13.98M | 693.00K | 0.00 | Net Debt |
| -51.10M | -57.06M | -96.61M | -218.57M | -137.79M | -21.60M | Total Liabilities |
| 25.81M | 25.56M | 42.55M | 31.85M | 306.98M | 46.87M | Stockholders Equity |
| 56.68M | 69.12M | 126.74M | 233.98M | -108.57M | -21.14M |
| Cash Flow | Free Cash Flow | ||||
| -40.23M | -53.73M | -101.75M | -174.25M | -95.22M | -24.90M | Operating Cash Flow |
| -40.26M | -53.24M | -100.14M | -171.38M | -87.02M | -24.33M | Investing Cash Flow |
| 137.00K | -486.00K | -1.61M | -2.87M | -8.20M | -578.00K | Financing Cash Flow |
| 2.00K | 33.00K | 406.00K | 234.43M | 246.75M | 39.61M |
Talis Biomedical Technical Analysis
Positive
1.74
Price Trends
1.67
Positive
1.71
Positive
3.35
Negative
Market Momentum
0.02
Negative
61.48
Neutral
85.19
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TLIS, the sentiment is Positive. The current price of 1.74 is above the 20-day moving average (MA) of 1.66, above the 50-day MA of 1.67, and below the 200-day MA of 3.35, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 61.48 is Neutral, neither overbought nor oversold. The STOCH value of 85.19 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TLIS.
Talis Biomedical Risk Analysis
Talis Biomedical disclosed 79 risk factors in its most recent earnings report. Talis Biomedical reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Talis Biomedical Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $18.57B | 21.83 | 13.24% | 1.79% | 6.70% | 2.56% | |
67 Neutral | $19.46B | ― | -19.42% | ― | 56.75% | 59.77% | |
52 Neutral | $256.56M | 25.27 | -4.64% | ― | -54.17% | -135.78% | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 19.94% | 1.20% | |
46 Neutral | $74.38M | ― | -80.11% | ― | -7.43% | 69.03% | |
46 Neutral | $2.35B | ― | -50.74% | ― | -7.03% | -20233.78% | |
29 Underperform | $55.13M | ― | -89.71% | ― | -70.65% | 41.59% |
* Healthcare Sector Average
Performance Comparison
TLIS
Talis Biomedical
1.74
-6.76
-79.53%
VERU
Veru
0.51
-0.25
-32.89%
OSUR
Orasure Technologies
3.43
-2.65
-43.59%
DGX
Quest Diagnostics
167.33
35.35
26.78%
QDEL
QuidelOrtho
34.89
-12.11
-25.77%
NTRA
Natera
143.94
50.98
54.84%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.